ClinicalTrials.gg
RecruitingNCT06492863Updated Jul 9, 2024

Gene Therapy(FT-003) for Wet AMD

A Phase 1/2 interventional study of FT-003 in Neovascular Age-related Macular Degeneration, sponsored by Frontera Therapeutics. Recruiting at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-09.

Sponsored by Frontera Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Aug 2023, registered Jul 2024).
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
40th of 91
78 · median 62
Started
2023
with 13 others
Phase 1/2
18 of 107
8 open now
Primary completion
2024-10
later than 3 of 42 live
Registered
79th of 107
by date

Among the 107 studies in Macular Degeneration with a site in China, this one is the 40th largest by planned enrollment of the 91 interventional ones that give a count, is one of 14 that started in 2023, is one of 18 in phase 1/2, reaches primary completion later than 3 of the 42 other live ones, and was the 79th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 107 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with neovascular age-related Macular Degeneration (nAMD). The study was divided into two phases, Phase 1 dose escalation and Phase II dose expansion.

Read the detailed description

FT-003 is a gene therapy product developed for the treatment of neovascular age-related macular degeneration (nAMD). Neovascular AMD is the main cause of blindness among elderly individuals. The available therapies for treating nAMD require life-long intravitreal (IVT) injections every 4-12 weeks to maintain efficacy. Administration of FT-003 has the potential to treat nAMD by providing durable expression of therapeutic levels of intraocular protein and maintaining the vision of patients. FT-003 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration

Keywords

  • FT-003
  • nAMD
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects that are willing and able to follow study procedures;
  • Female or male patients 50-80 years old at the time of signing the ICF;
  • Clinically diagnosed with nAMD;
  • Presence of active CNV
  • The best corrected visual acuity (BCVA) of the studied eye is 24-73 letters;

Exclusion criteria

Exclusion Criteria:

  • •Presence of any other intraocular diseases other than nAMD in the studied eye that would affect the improvement of visual acuity and require treatment during the study for prevention or treatment of visual loss, as judged by the investigator.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    FT003 Dose 1

    Low dose of FT-003

    Genetic: FT-003

  • Experimental
    FT003 Dose 2

    Mid dose of FT-003

    Genetic: FT-003

  • Experimental
    FT003 Dose 3

    High dose of FT-003

    Genetic: FT-003

Interventions

  • GeneticFT-003

    Administered via intraocular injection.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability after FT-003 injection

    Incidence and severity of AE (Common Terminology Criteria for Adverse Events 5.0)

    Time frame: At Week 12

Secondary outcomes

  1. To evaluate the efficacy after FT-003 injection

    the BCVA and OCT change from baseline

    Time frame: At Week 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Oct 2024, 14 months after the start.

Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Jul 9, 2024
StartActual
Aug 15, 2023
Primary completionEst.
Oct 15, 2024
CompletionEst.
Oct 15, 2028
Last update
Jul 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06492863
Lead sponsor
Frontera Therapeutics
Collaborators
Tianjin Medical University Eye Hospital, The First Affiliated Hospital of Soochow University, Peking Union Medical College Hospital, Beijing Hospital
Responsible party
Sponsor
First posted
Jul 9, 2024
Start date
Aug 15, 2023
Primary completion
Oct 15, 2024 (estimated)
Completion
Oct 15, 2028 (estimated)
Last update
Jul 9, 2024

Study contacts

Xinyan Li
Contact
xinyan.li@fronteratherapeutics.com
86-021-58206061
Minghui Xue
Contact
minghui.xue@fronteratherapeutics.com
86-021-58206061
Xiaorong Li, Professor
principal investigator · Tianjin Medical University Eye Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion